Tanja Laschober PhD

Dr. Laschober is a Research Scientist at the Addictions, Drug & Alcohol Institute. She is currently the National Project Director of CTN Protocol 0110 Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB) and CTN Protocol 0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and MSM-Centered Community Based Organizations (CBOs) for the Pacific Northwest Node of The National Drug Abuse Treatment Clinical Trials Network (CTN).

Dr. Laschober’s experience includes project management, data management, quantitative analysis, writing, and dissemination of findings. She provides statistical, grant-writing, and manuscript-writing support to members of the Pacific Northwest Node. She also serves as a reviewer for the CTN Publications Committee.

Her previous research has focused on the adoption, implementation, and sustainability of evidence-based practices; evaluation of mandatory smoking cessation policies; and workforce development in substance use disorder treatment programs. She also has experience with interventions to safely disclose HIV-positive status among men who have sex with men.